ReShape Lifesciences Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Paul Hickey

Directeur général

US$506.4k

Rémunération totale

Pourcentage du salaire du PDG	73.7%
Durée du mandat du directeur général	2.3yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	2.3yrs
Durée moyenne du mandat des membres du conseil d'administration	6.4yrs

Mises à jour récentes de la gestion

Recent updates

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

Apr 18

ReShape wins FDA clearance for device used in weight loss surgery

Aug 10

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Mar 31

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Dec 09

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Aug 24

Analyse de la rémunération des PDG

Comment la rémunération de Paul Hickey a-t-elle évolué par rapport aux bénéfices de ReShape Lifesciences?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$7m
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$506k	US$373k	-US$11m
Sep 30 2023	n/a	n/a	-US$26m
Jun 30 2023	n/a	n/a	-US$35m
Mar 31 2023	n/a	n/a	-US$41m
Dec 31 2022	US$158k	US$133k	-US$46m

Rémunération vs marché: La rémunération totale de Paul ($USD 506.42K ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 647.72K ).

Rémunération et revenus: La rémunération de Paul a augmenté alors que l'entreprise n'est pas rentable.

PDG

Paul Hickey (59 yo)

2.3yrs

Titularisation

US$506,416

Compensation

Mr. Paul F. Hickey is Chief Executive Officer, President and Director at ReShape Lifesciences Inc. from August 15, 2022. He served as Senior Vice President of Marketing and Reimbursement at EnteroMedics In...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Dan Gladney	Executive Chair	9yrs	US$129.50k	0.0028% $ 77.6
Paul Hickey	CEO, President & Director	2.3yrs	US$506.42k	pas de données
Thomas Stankovich	Senior VP & CFO	5.1yrs	US$307.12k	0.078% $ 2.2k
Mark Knudson	Co-Founder and Special Advisor to the CEO	no data	US$396.98k	pas de données
Katherine Tweden	Co-Founder	no data	US$240.67k	pas de données
Al Diaz	Vice President of Operations and R&D	3.3yrs	pas de données	pas de données
Dov Gal	VP of Regulatory Clinical Quality & Compliance Officer	no data	pas de données	pas de données
Jody Dahlman	Director of Communications	no data	pas de données	pas de données
Naqeeb Ansari	Senior Vice President of Global Commercial Operations	2.2yrs	US$1.16m	pas de données

2.3yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Gestion expérimentée: L'équipe de direction de RSLS est considérée comme expérimentée (ancienneté moyenne 2.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Dan Gladney	Executive Chair	9yrs	US$129.50k	0.0028% $ 77.6
Paul Hickey	CEO, President & Director	2.3yrs	US$506.42k	pas de données
Ardaeviraf Minocherhomjee	Independent Director	6.3yrs	US$52.50k	pas de données
Gary Blackford	Independent Lead Director	8.3yrs	US$77.00k	pas de données
Philip Schauer	Member of Scientific Advisory Board	6.4yrs	pas de données	pas de données
Caroline Apovian	Member of Scientific Advisory Board	1.7yrs	pas de données	pas de données
Scott Shikora	Member of Scientific Advisory Board	6.4yrs	US$892.19k	pas de données
Lori McDougal	Independent Director	9.3yrs	US$57.50k	pas de données
Jaime Ponce	Member of Scientific Advisory Board	6.4yrs	pas de données	pas de données
John Morton	Member of Scientific Advisory Board	6.4yrs	pas de données	pas de données
Natan Zundel	Member of Scientific Advisory Board	6.4yrs	pas de données	pas de données
Michael Baptista	Member of Scientific Advisory Board	1.7yrs	pas de données	pas de données

6.4yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de RSLS sont considérés comme expérimentés (ancienneté moyenne 6.4 ans).

ReShape Lifesciences Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

Insufficient new directors

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

High number of new directors

Recent updates

Third quarter 2024 earnings released: US$3.12 loss per share (vs US$59.37 loss in 3Q 2023)

ReShape Lifesciences Inc. to Report Q3, 2024 Results on Nov 14, 2024

ReShape Lifesciences Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences Inc. announced that it expects to receive $0.833333 million in funding

Second quarter 2024 earnings released: US$0.063 loss per share (vs US$1.08 loss in 2Q 2023)

ReShape Lifesciences Inc. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q1, 2024 Results on May 15, 2024

The Nasdaq Stock Market Determines ReShape Lifesciences Eligible for an Additional 180 Calendar Period, or Until October 7, 2024, to Regain Compliance with Minimum Bid Price Requirement

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System

Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

Consensus EPS estimates upgraded to US$3.84 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q3, 2023 Results on Nov 08, 2023

ReShape Lifesciences Receives Non-Compliance Notice From Nasdaq

ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device

Consensus revenue estimates decrease by 23%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q2, 2023 Results on Aug 07, 2023

ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting

ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0

Consensus EPS estimates upgraded to US$5.85 loss, revenue downgraded

ReShape Lifesciences Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus EPS estimates upgraded to US$16.50 loss

Full year 2022 earnings: EPS misses analyst expectations

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

Consensus revenue estimates fall by 16%

ReShape Lifesciences Inc. Provides Revenue Guidance

Price target decreased to US$1.03

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$1.48 loss in 3Q 2021)

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

ReShape Lifesciences Inc. to Report Q3, 2022 Results on Nov 14, 2022

Reshape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

ReShape Lifesciences Announces Release of Positive Consensus Statement on Lap-Band Use and Lap-Band Aftercare Management by American Society of Metabolic and Bariatric Surgery

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Inc. announced delayed 10-Q filing

Price target decreased to US$3.08

Insufficient new directors

Reshape Lifesciences™ Receives FDA 510(K) Clearance for the Gibi Hd™ Calibration Tubes for Use in Gastric and Bariatric Procedures

ReShape wins FDA clearance for device used in weight loss surgery

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

ReShape Lifesciences Receives Non-Compliance Notice from Nasdaq

ReShape Lifesciences Inc. to Report Q1, 2022 Results on May 23, 2022

ReShape Lifesciences Inc. announced delayed 10-Q filing

ReShape Lifesciences Inc. announced delayed annual 10-K filing

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$0.74 loss in 3Q 2020)

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$0.52 loss in 2Q 2020)

High number of new directors

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$12.00

ReShape Lifesciences Inc. (OTCPK:RSLS) completed the acquisition of Obalon Therapeutics, Inc. (NasdaqCM:OBLN) in a reverse merger transaction.

ReShape Lifesciences Inc. (OTCPK:RSLS) entered into an agreement to acquire Obalon Therapeutics, Inc. (NasdaqCM:OBLN).

ReShape Lifesciences Inc. to Report Q2, 2020 Results on Aug 13, 2020

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen